These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Successful paroxetine treatment of major depression in an adult form of metachromatic leukodystrophy with cognitive disturbances. Vella G; Loriedo C; Raccah R; Baldassarre P; Paolillo A Can J Psychiatry; 1998 Sep; 43(7):748-9. PubMed ID: 9773228 [No Abstract] [Full Text] [Related]
7. Withdrawal after discontinuation of paroxetine. Arya DK Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183 [No Abstract] [Full Text] [Related]
8. Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine--a case report. Amiaz R; Stein O; Dannon PN; Grunhaus L; Schreiber S Psychopharmacology (Berl); 1999 Apr; 143(4):433-4. PubMed ID: 10367562 [No Abstract] [Full Text] [Related]
9. Olanzapine in the treatment of resistant depression. Caetano D; Caetano SC Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713 [No Abstract] [Full Text] [Related]
11. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Kuhs H; Schlake HP; Rolf LH; Rudolf GA Acta Psychiatr Scand; 1992 May; 85(5):364-9. PubMed ID: 1534961 [TBL] [Abstract][Full Text] [Related]
12. Exacerbation of extrapyramidal symptoms with paroxetine. Arya DK; McKenzie J; Worrall N Aust N Z J Psychiatry; 1995 Sep; 29(3):521-2. PubMed ID: 8573063 [No Abstract] [Full Text] [Related]
13. Paroxetine for the prevention of depression induced by interferon alfa. Kraus MR; Schäfer A; Scheurlen M N Engl J Med; 2001 Aug; 345(5):375-6. PubMed ID: 11484704 [No Abstract] [Full Text] [Related]
14. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Ko HC; Lu RB; Shiah IS; Hwang CC Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of depression: the role of paroxetine. Deahl M Hosp Med; 2001 Jan; 62(1):38-42. PubMed ID: 11211460 [TBL] [Abstract][Full Text] [Related]
16. Cost analysis of paroxetine versus imipramine in major depression. Bentkover JD; Feighner JP Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618 [TBL] [Abstract][Full Text] [Related]
17. Paroxetine treatment of depression in late life. Reynolds CF Psychopharmacol Bull; 2003; 37 Suppl 1():123-34. PubMed ID: 14566207 [TBL] [Abstract][Full Text] [Related]
18. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression? Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218 [TBL] [Abstract][Full Text] [Related]
19. Reversible hepatotoxicity of paroxetine in a patient with major depression. Helmchen C; Boerner RJ; Meyendorf R; Hegerl U Pharmacopsychiatry; 1996 Nov; 29(6):223-6. PubMed ID: 8956353 [TBL] [Abstract][Full Text] [Related]
20. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]